NEW YORK – Spatial biology firm Stellaromics said Tuesday that it has raised $80 million in a Series B financing round.
The round was led by Catalyst4, with participation from Stanford University Ventures. Stellaromics said the money raised will help support the development and commercialization of the company's newly unveiled spatial biology platform, Pyxa.
Based upon Stellaromics' Starmap and Ribomap technologies, Pyxa promises to analyze both thin and thick tissue sections with subcellular resolution. The company said the Pyxa system, which is slated to launch in the second half of this year, is available for order now with an early-access program "already fully subscribed." The company estimates commercial shipments of the platform will begin at the end of 2025.
To support researchers interested in generating pilot data with Pyxa, Stellaromics also currently offers a services program using the platform.
Founded in 2022, Stellaromics is a spinout of Karl Deisseroth's lab at Stanford University and Xiao Wang's lab from MIT and the Broad Institute. The Boston-based company previously raised $25 million in Series A funding to support the R&D and early-access programs for its spatial omics technology.
"By providing a true three-dimensional multiomic representation of biological systems, Pyxa will empower researchers to make breakthrough discoveries that deepen our understanding of human biology and accelerate the development of new diagnostics and therapeutics," Stellaromics CEO Todd Dickinson said in a statement.